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Abstract 
Background Psoriasis Area and Severity Index (PASI) 75 response is currently considered the 
gold standard for assessing treatment efficacy in moderate-to-severe psoriatic patients. PASI 90 
response denotes better clinical improvement compared to PASI 75. Very few studies have 
assessed if a greater PASI clinical response is associated with greater improvements in 
Dermatology Life Quality Index (DLQI). A systematic review and meta-analysis was performed 
to assess the association between PASI response and DLQI. 
Objective The study was conducted to assess whether greater improvement in PASI scores from 
PASI 75-89 to PASI 90 is associated with greater Quality of life (QoL) improvements 
specifically Dermatology Life Quality Index (DLQI) scores.  
Methods Systematic searches were conducted in MEDLINE, Embase, and Cochrane Library to 
identify studies evaluating biologic interventions in adult moderate to severe psoriasis patients 
reporting PASI response and their corresponding DLQI change from baseline score. The quality 
of evidence was assessed through Jadad score for randomized controlled trials and Downs and 
Black’s checklist for observational studies.  
Results Meta-analysis estimated change from Baseline in DLQI for PASI 75-89 responders to be 
78% (95% credible intervals [CrI]: 75%-82%) and for PASI 90 responders to be 90% (95% CrI 
88%-93%). This implies 12% greater improvement in DLQI score for PASI 90 responders 
compared with PASI 75-89 responders. In addition, the meta-analysis also showed a statistically 
significant difference in DLQI score of 0/1 between PASI 75-89 and PASI 90 responders (45% 
[95% Crl]; 41.0%-50.0% and 73% [95% Crl]; 70.0%-76.0%) respectively, Bayesian p-
value<0.0001).  
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Conclusion In conclusion, substantial improvement in clinical efficacy is associated with 
improved quality of life (QoL) in moderate-to-severe psoriatic patients suggesting that PASI 90 
responders (clear or almost clear skin) could achieve a superior QoL compared to PASI 75-89 
responders. 
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Introduction 
Psoriasis, a chronic, relapsing, immune-mediated, inflammatory skin disease affecting 
approximately 2–3% of the population is associated with a significant disease burden.1 A report 
by the International Federation of Psoriasis Associations indicates that in the US there is an 
approximate loss of 56 million hours of work and USD 2-3 billions spent on treatment every year 
(http://www.ifpa-pso.org/, accessed 18 Jan 2016). The World Health Organization (WHO) also 
recognizes psoriasis as a serious non-communicable disease. Patients with psoriasis also have an 
increased risk of developing co-morbid conditions such as psoriatic arthritis, cardiovascular 
diseases, infections, malignancies, and autoimmune diseases.2 Therefore, patients with psoriasis 
have a significantly compromised health-related quality of life (HRQoL),3 leaving them stressed, 
socially withdrawn, and importantly, with suicidal tendency.4-7 Approximately 25%–44% of 
patients have moderate to severe disease,8 and need an aggressive treatment due to increased 
severity of symptoms.9,10 
The goal of treatment is to reduce the signs and symptoms of the disease, possibly slowing the 
natural progression of the disease. Available systemic biologic treatments target the 
pathophysiological pathways modulated by several cytokines.11 Currently available options 
available in this class of drugs include anti-TNF agents (infliximab, adalimumab, and 
etanercept), anti-interleukin (IL)-12/23 (ustekinumab) and IL-17A agents (secukinumab).12,13 
The Psoriasis Area and Severity Index (PASI) remains the most common efficacy endpoint in 
clinical trials and is considered as a gold standard since it accounts for both severity (erythema, 
induration and desquamation) and extent of disease (head, trunk, arms and legs).14 However, the 
benefit remains incomplete if this does not translate into improved quality of life. Therefore, 
evaluating the impact on patients’ quality of life (QoL) following treatment, and therefore, any 
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reduction in the disease burden seems one of the most important aspects of treatment considering 
the tormenting impact of psoriasis. This is especially pertinent since treatment with biologic 
agents is costly, and would be appreciated when reflects in an improvement in the QoL.  
Keeping this in view, we performed a systematic review and meta-analysis to understand if the 
improvement in PASI scores results in an overall improved QoL in adult patients with moderate 
to severe psoriasis where patients were treated with one of the approved systemic biologic 
agents. PASI was specifically chosen as the clinical efficacy endpoint of interest as it is the most 
commonly used score in psoriasis trials, making meta-analysis of existing trials possible.15 A 
75% or greater improvement from Baseline (PASI 75) is widely accepted as a useful and realistic 
clinical outcome. Importantly, PASI 90, meaning a 90% or greater improvement from Baseline, 
fulfills the European regulatory definition of therapeutic success16 and appears to be better 
correlated with improved HRQoL compared with PASI 75.17 For evaluating the impact on QoL 
we used Dermatology Life Quality Index (DLQI),18 a commonly used PRO in psoriasis trials.15 
The treatment goal for DLQI can be defined as a score of 0 or 1, implying that patient’s QoL is 
not affected by psoriasis.19  Patients achieving PASI 90 will have better clinical improvement 
compared to PASI 75.  Almost clear skin (PASI 90) will be beneficial for patients if it leads to 
better quality of life (DLQI score). Here, we present the results from this systematic review, and 
meta-analysis from five clinical trials.   
Materials and Methods 
This systematic review and meta-analysis were conducted in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement.20 The 
selection of databases, eligibility criteria, outcomes of the review, and analyses methods were 
defined a priori in an internal protocol. Study selection, data extraction, and quality assessment 
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were performed independently by two assessors. Any discrepancy was reconciled by a third 
independent reviewer. 
Searches and Data Extraction 
A comprehensive literature search of MEDLINE (including Medline-in-Process), PubMed, 
EMBASE, the Cochrane Centre Register of Controlled Trials, and National Health Service 
Economic Evaluation Database was carried out in Ovid for relevant articles for last 10 years 
(2004 – 2014). The detailed search strategy is presented in Table 1. 
Table 1 to be inserted here 
Published articles were included if they investigated one of the following treatments: all disease 
modifying anti-rheumatic drugs (DMARDs) including biologics used for psoriasis treatment. 
The comparisons had to be done either versus a placebo or an active treatment. Study design 
included RCTs (with any blinding status), Non-RCTs, and observational studies. There was no 
restriction on treatment duration. Patient population consisted of adults (≥18 years of age) of any 
gender/race with moderate to severe psoriasis. The inclusion criteria in the clinical trials and 
studies were in line with the definition of moderate to severe psoriasis. Studies had to report at 
least one outcome of interest i.e., PASI 75-89 (≥ 75% to <90% improvement (reduction) in PASI 
score with respect to baseline), PASI 90 (≥ 90% improvement (reduction) in PASI score), PASI 
100 (complete clearance of psoriasis corresponds to absolute score PASI=0), and their 
corresponding DLQI 0/1 response rates. Data were segregated by the time-point according to 
different outcomes reported, both for the randomised phase or the long-term maintenance phase.  
Only articles in English language were included. Exclusion criteria were as follows: use of 
conventional interventions, no subgroup analysis for disease of interest, and studies not reporting 
secondary outcomes data (QoL) for the primary outcome of interest (PASI response). 
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After exclusion of duplicates, titles and abstracts were screened for inclusion and exclusion. 
Potentially relevant articles were checked in full text for inclusion. Study characteristics (e.g. 
study design, phase, blinding status, sample size), study population (e.g. age, sex, duration of 
psoriasis), and study results of included trials were extracted using a standardised form. Primary 
outcomes were PASI response defined as PASI 75-89, PASI 90 and PASI 100. Secondary 
outcomes included DLQI response of 0/1, defined as final DLQI equal to 0 or 1, DLQI score 
mean percentage change from Baseline, and DLQI score mean change from Baseline. 
Quality assessment 
The Jadad scoring system was used to appraise adequacy of randomisation, blinding, and 
reporting of withdrawals/discontinuations for RCTs while the Downs and Black’s checklist was 
used to appraise the non-RCTs. Four studies attained a maximum score of 5 on the Jadad scale, 
suggesting adequate reporting of randomisation, blinding, and reporting of 
withdrawals/discontinuations. While one study17 had the score of three, no other study reported a 
Jadad score of less than 4 indicating that studies included in the review were of good quality. The 
use of adequate method of allocation concealment was reported in all the included studies, 
resulting in allocation concealment grade 'A'. None of the studies reported an inadequate method 
of allocation concealment or that method of concealment was not used in the study. The open-
label single arm trials were of good quality in terms of reporting and assessment of bias – one 
study21 scored 16 and other study17scored 18 on the Downs and Black’s checklist. 
Data analysis 
Meta-analysis is a statistical technique to combine multiple estimates of a quantity into a single 
estimate.22 It is most commonly used to combine estimates of treatment effects from multiple 
trials but can be used to synthesise estimates of any quantity, as is often necessary in medical 
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decision making.23 For the current SR, Bayesian meta-analysis was used to combine estimates of 
DLQI improvement in PASI responder subgroups when three or more studies are available. If 
sufficient data was available to fit both, a choice between fixed and random effects models was 
made on the basis of lowest Deviance Information Criterion (DIC) and residual deviance.24, 25  
The continuous data included DLQI score mean percentage change from Baseline and DLQI 
score mean change from Baseline. The dichotomous data was DLQI response of 0/1. Relative 
risks with 95% CrI for dichotomous data and mean differences with 95% CrI for continuous data 
were calculated. Classical statistically significant differences between DLQI effect in PASI 75-
89 and PASI 90 responders, at 0.05 level, were assessed using one-sided Bayesian p-values; 
these are the Bayesian probability that DLQI effect was greater in one responder group than the 
other. Meta-analysis of studies was conducted using OpenBUGS (version 3.2.2 rev 1063).26  
Meta-analysis of studies reporting DLQI percentage change from Baseline and DLQI response of 
0/1 was conducted for PASI75-89 and PASI90 separately. Sample size weighted averages were 
used to impute mean and standard deviation of DLQI percentage change from baseline in studies 
that did not directly report for PASI75-89 or PASI90. 
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Results 
Systematic search in databases (MEDLINE, EMBASE, and Cochrane Library) yielded 1085 
results. Due to the overlap of records across the databases searched, 292 abstracts were identified 
as duplicates. Following the first screening of these citations according to their titles and 
abstracts, 264 potentially relevant references were identified. A detailed evaluation of full-text 
reports of these citations was performed, and 251 studies were excluded due to non-reporting of 
the secondary outcome data (i.e. DLQI) for the patients achieving PASI 75-89 and PASI 90 
responses. None of the studies reported secondary outcome data for PASI 100 (Fig. 1). Of total 
13 studies extracted, four studies met the predefined eligibility criteria for inclusion in this meta-
analysis, and all included patients with moderate to severe psoriasis. Apart from the four studies 
identified from systematic literature search, recently published results from CLEAR study were 
also included in the meta-analysis. CLEAR, a head-to-head trial, compared the efficacy and 
safety of secukinumab with ustekinumab in subjects with moderate to severe plaque psoriasis.  
 
Figure 1 to be inserted here 
Primary objective of CLEAR study was to demonstrate superiority of secukinumab versus 
ustekinumab with respect to PASI 90 response at week 16. DLQI response was also reported in 
the study (Thaci et al., 2015). The details of the demographics and disease characteristics of 
study participants at Baseline are listed in Table 2. Baseline demographics and clinical disease 
characteristics were comparable across the included studies. The mean age of the patients in the 
randomised controlled trials (RCTs) was about 40 years, and >65% patients were male. The 
mean duration of disease ranged from 15 to 18.8 years.  
Table 2 to be inserted here 
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Qualitative analysis 
Patients achieving primary efficacy end-point (10-16 weeks) 
Studies included in the analysis of the randomised phase of the trials assessing the correlation 
between PASI response and QoL are listed in Table 3.  
Table 3 to be inserted here 
 
DLQI mean change from Baseline 
Two studies reported data for mean change from Baseline in DLQI score for both PASI 75-89 
and PASI 90 responders.21, 27 Kalb 2013 only reported DLQI score for PASI>=75 and PASI 90 
but PASI75-89 could be imputed as score in PASI>=75 is the weighted average of PASI75-89 
and PASI 90; the imputed mean DLQI change from baseline was -8.33, with standard deviation 
14.46 and sample size of 50.21 Score for PASI 90 in Revicki 2008 was imputed as the weighted 
average of PASI 90-99 and PASI>=100; the mean change was -10.48 with standard deviation 
5.11 and sample size 447.27 
Meta-analysing these results, the mean reduction from Baseline in DLQI score, i.e. 
improvement,  were greater for PASI 90 responders as compared with PASI 75-89 responders 
(Fig. 2). This difference was statistically significant in the pooled CHAMPION and REVEAL 
trials.27  
Figure 2 to be inserted here 
 
DLQI percent improvement from Baseline 
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Only one study reported data for mean percent improvement from Baseline in DLQI score for 
both PASI 75-89 and PASI 90 responders. The mean percent improvement from Baseline in 
DLQI score was greater for PASI 90 responders as compared with PASI 75-89 responders (91% 
vs. 75%, respectively).28 
DLQI 0/1 response 
Two studies reported data for DLQI response of 0/1 for PASI 75-89 and PASI 90 responders.28, 
29 In both studies, greater proportion of PASI 90 responders achieved a DLQI response of 0/1 as 
compared with PASI 75-89 responders (Fig. 3). This difference was statistically significant for 
studies with secukinumab (p<0.001).29  
Patients on maintenance phase (26-52 weeks) 
Studies included in the analysis of the maintenance phase of the trials assessing the correlation 
between PASI response and QoL are listed in Table 3. 
Table 3 to be inserted here 
 
DLQI 0/1 response 
Two studies reported data for DLQI response of 0/1 for PASI 75-89 and PASI 90 responders.17,29 
In both studies, greater proportion of PASI 90 responders achieved a DLQI response of 0/1 as 
compared with PASI 75-89 responders (74% vs 56.7% and 85.71% vs 50%, respectively). This 
difference was statistically significant for studies with secukinumab (p<0.001).29 
DLQI score mean change from Baseline 
The mean reduction from Baseline in DLQI score, i.e. improvement, was greater for PASI 90 
responders as compared with PASI 75-89 responders (-8.62 vs. -8.2, respectively) at Week 26.21 
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Meta-analysis 
Only two studies reported DLQI 0/1 response and one study reported DLQI mean change at 
maintenance phase so only the primary efficacy end-point (10-16 weeks) was meta-analyzed. 
Patients achieving primary efficacy end-point (10-16 weeks) 
Percentage change in mean DLQI from Baseline 
Four studies including the Novartis CLEAR study reported change in DLQI for PASI 75-89 and 
PASI 90 responders.21,27,29 Using a fixed effects model, the mean percentage reduction from 
Baseline in DLQI scores, i.e. improvement, was greater (Bayesian probability >99.99%) in PASI 
90 responders (90% [95% Credible Intervals, CrI: 88%, 93%]) as compared with PASI 75-89 
responders (78% [95% CrI: 75%, 82%]). A forest plot for the studies included in this meta-
analysis is presented in Fig. 4.  
Figure 4 to be inserted here 
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DLQI 0/1 response 
Three studies including Novartis CLEAR study reported data for DLQI response of 0/1 for PASI 
75-89 and PASI 90 responders.28,29 Using a fixed effects model, a greater proportion of PASI 90 
responders (Bayesian probability > 99.99%) achieved a DLQI score of 0/1 (76% [95% CrI: 70%, 
76%]) as compared with PASI 75-89 responders (45% [95% CrI: 41%, 50%]). A forest plot for 
the studies included in this meta-analysis is presented in Fig. 5. 
Figure 5 to be inserted here 
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Discussion 
The present analysis demonstrated that improvement in QoL as evaluated by DLQI score was 
commensurate with a higher clinical response as evaluated by PASI response. Overall, the 
improvement in QoL was greater in PASI 90 responders as compared with PASI 75-89 
responders in both short- and long-term. The improvement in QoL was sustained over 26-52 
weeks in PASI 90 responders while being in maintenance phase.  
The present systematic review and meta-analysis focused on an important outcome in psoriasis 
trials, i.e. the clinical improvement, and the benefit based on PRO, both critical to establishing 
the therapeutic effectiveness and satisfaction with treatment, especially biologics. This is 
principally pertinent because of two reasons. First, psoriasis is associated with significant 
negative impact on emotional, physical, psychological, and social functioning, and second is the 
cost consideration for treatment with biologics.  
The data from studies included in this systematic review demonstrated a consistent association 
between the clinical response as assessed by PASI 75-89 and PASI 90, and disease-specific QoL 
as assessed by DLQI during a short-term treatment (10-16 weeks); the reduction in PASI scores 
was directly associated with the improvement in DLQI scores. PASI 90 responders had a greater 
improvement in DLQI scores as compared with PASI 75-89 responders, which reflected the 
clinical benefit with QoL. The mean percentage reduction from Baseline in DLQI scores was 
greater in PASI 90 responders as compared with PASI 75-89 responders (91% vs. 75%, 
respectively).28 This additional 16% improvement in DLQI scores for PASI 90 responders versus 
PASI 75-89 responders seems meaningful. Similar and sustained benefit was noted during long-
term maintenance phase (26-52 weeks). The 52-week maintenance phase data showed that a 
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significantly greater proportion of PASI 90 responders achieved a DLQI score of 0/1 versus 
PASI 75-89 responders,29 suggesting a sustained improvement in clinical response, and QoL.  
Meta-analysis estimated a 78% and 90% change from Baseline in DLQI scores for PASI 75-89 
and PASI 90 responders, respectively, at the primary endpoint of 10-16 weeks. Similarly, a 
greater proportion of patients achieved a DLQI score of 0/1 representing no impact on QoL as 
compared with PASI 75-89 responders (73% vs. 45%). These results are consistent with data 
reported for individual studies where a better clinical response was associated with an improved 
QoL.28,29 Similar results were reported by a recent review where PASI 75 responders had a 
significant reduction in mean DLQI scores as compared to those having a 50–75% or <50% 
PASI response.30 
Overall, a consistent trend of association was observed between improvement in PASI and DLQI 
scores; a reduction in PASI score was directly related with the improvement in DLQI. This 
supports the importance from the patients’ QoL perspective of achieving the highest possible 
response, PASI90. The treatment options provided should include therapies which can achieve 
higher proportion of patients with PASI 90 or above scores resulting in better QoL for patients 
with psoriasis. 
These analyses provide evidence of superiority in DLQI outcomes in PASI 90 compared to PASI 
75-89 responders. However, there are certain limitations that should be considered while 
interpreting the results of this review. There were limited publications with relevant data 
corresponding to the spectrum of PASI improvement. Also, the study conclusion was based on 
studies that reported DLQI data; results of other HRQoL tools were not adequately reported. 
There was also insufficient evidence available for meta-analysis at the maintenance phase so 
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longer term effects are uncertain.There was also lack of real world evidence to support the 
conclusions.  
It was not possible to do meta-analyses looking at correlation between PASI75-89 and PASI90 
response and mean change DLQI and DLQI score of 0/1 in subgroups stratified by age, sex or 
other covariates due to the limited number of studies included in the analyses (there were only 4 
studies in the mean change DLQI analysis and 3 in the DLQI score of 0/1 analysis), and none of 
the published studies (PSUNRISE, CHAMPION, REVEAL) reported the requisite subgroups. 
While it would be possible to re-analyse the FIXTURE, ERASURE and CLEAR data to obtain 
the subgroup information, this would still lead to a very limited evidence base for meta-analysis. 
Findings showed PASI 90 translated into greater QoL compared with PASI 75-89 in both short- 
and long-term but the underlying causal explanations remains unknown. More research is needed 
to explore and interpret the association between PASI and DLQI. 
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Tables  
 
Table 1. List of search terms used for retrieving relevant studies from various databases 
Search criteria Search terms/strings 
Disease exp *psoriasis/ 
PASI ((psoriasis area and severity index) or (psoriasis area severity index or PASI 
or PASI score or psoriasis area severity index 75 or PASI 75 or psoriasis 
area severity index 90 or PASI 90 or psoriasis area severity index 100 or 
PASI 100)).mp. 
Comorbidities (comorbidit* or co-morbidit*).mp. 
Quality of life 
 
(quality of life or quality-of-life or QoL or disab* or morbid* or mortalit* 
or patient reported outcome or patient-reported outcome or PRO or Quality 
adjusted life years or QALY or Disability adjusted life years or Quality-
adjusted life years or Disability-adjusted life years or DALY or prefer* or 
questionnaire or scale or score or satisfact* or utilit* or dermatology life 
quality index or DLQI or EQ-5D).mp. 
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Table 2. The demographics and disease characteristics of study participants at Baseline 
Trial Name Interventions Number of 
participants 
Gender Age (years) 
Mean (SD) 
Duration of 
psoriasis 
(years) 
Mean (SD) 
Male 
n (%) 
Female 
n (%) 
PSUNRISE 
trial 
Infliximab 5 mg/kg 215 137 (63.7)  44.4 (13.3) 18.8 (11.4) 
CHAMPION 
& REVEAL 
trials 
Adalimumab 
pooled 
1469 971 (66.1) 498 (33.9) 44.1 (13.1) 18.6 (11.6) 
CHAMPION 
trial 
Adalimumab 40 
mg EOW 
108 70 (64.8) 37 (35.2) 44.1 (13.2) 18.6 (12) 
Placebo 53 35 (66) 18 (34.0) 45.4 (13.4) 18.8 (12) 
ERASURE 
trial 
Secukinumab 
300 mg 
245 169 (69.0) 76 (31.0) 44.9 (13.5) 17.4 (11.1) 
Secukinumab 
150 mg 
245 168 (68.6) 77 (31.4) 44.9 (13.3) 17.5 (12.0) 
Placebo 248 172 (69.4) 76 (30.6) 45.4 (12.6) 17.3 (12.4) 
FIXTURE 
trial 
Secukinumab 
300 mg 
327 224 (68.5) 103 (31.5) 44.5 (13.2) 15.8 (12.3) 
Secukinumab 
150 mg 
327 236 (72.2) 91 (27.8) 45.4 (12.9) 17.3 (12.2) 
Etanercept 50 mg 326 232 (71.2) 94 (28.8) 43.8 (13.0) 16.4 (12.0) 
Placebo 326 237 (72.7) 89 (27.3) 44.1 (12.6) 16.6 (11.6) 
CLEAR trial Secukinumab 
300 mg 
Ustekinumab 
337 
339 
229 (68) 
252 (74.3) 
108 (32) 
87 (25.7) 
45.2 (13.96) 
44.6 (13.67) 
19.6 (12.9) 
16.1 (11.24) 
EOW= every other week 
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Table 3. List of studies included in the analysis of the primary efficacy endpoint at 10-16 
weeks and meta-analysis 
Clinical trials included Source Interventions assessed 
 
PSUNRISE (single arm) Kalb 2013 Infliximab 
CHAMPION Navarini 2014 Adalimumab 
REVEAL Revicki 2007 Adalimumab 
ERASURE  Internal  Secukinumab 
FIXTURE  
CLEAR 
Internal 
Internal 
Secukinumab 
Secukinumab 
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Figure Legends 
 
Figure 1. PRISMA Flow for study inclusion 
Footnotes to Figure 1: PRISMA= Preferred Reporting Items for Systematic Reviews and Meta-
Analyses 
Figure 2. Mean change in DLQI score from Baseline by PASI responders 
Footnotes to Figure 2: DLQI= Dermatology Life Quality Index 
Figure 3. DLQI response by patients achieving PASI response 
Footnotes to Figure 3: DLQI= Dermatology Life Quality Index; PASI= Psoriasis Area and 
Severity Index 
Figure 4. Forest plot: DLQI change from Baseline – PASI 90 versus PASI 75-89 
Footnotes to Figure 4: DLQI= Dermatology Life Quality Index; PASI= Psoriasis Area and 
Severity Index 
Figure 5. Forest plot: DLQI 0/1 response – PASI 90 versus PASI 75-89 
Footnotes to Figure 5: DLQI= Dermatology Life Quality Index; PASI= Psoriasis Area and 
Severity Index 
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Figures 
 
 
 
Figure 1. PRISMA Flow for study inclusion 
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Figure 2. Mean change in DLQI score from Baseline by PASI responders 
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Figure 3. DLQI response by patients achieving PASI response 
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Figure 4. Forest plot: DLQI change from Baseline – PASI 90 versus PASI 75-89 
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Figure 5. Forest plot: DLQI 0/1 response – PASI 90 versus PASI 75-89 
